Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Silo Pharma Completed Pre-investigational New Drug Meeting With FDA For SPC-15, An Intranasal Prophylactic Treatment For Post-traumatic Stress Disorder And Stress-induced Anxiety Disorder

Author: Benzinga Newsdesk | September 10, 2024 06:36am

The primary purpose of the pre-IND meeting was to align with the FDA on the 505(b)(2) regulatory pathway for approval of SPC-15 along with Silo's proposed plan to support opening an IND. The FDA's 505(b)(2) drug development route can significantly shorten clinical timelines for FDA approval and reduce drug development costs.

Posted In: SILO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist